Home › Prostate Cancer › Tennessee
Prostate Cancer clinical trials in Tennessee
49 studies for Prostate Cancer are looking for participants at sites in Tennessee.
Cities in Tennessee
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Vanderbilt University/Ingram Cancer Center, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 28, 2026 · NCT06095089DESTINY-PANTUMOUR04
- Research Site, Nashville
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
- The Conrad Pearson Clinic, Germantown
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07832292Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Sarah Cannon Research Institute, Nashville
- Urology Associates, Nashville
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT06800313A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- The West Clinic, PLLC dba West Cancer Center ( Site 0063), Germantown
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06136650This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology PLLC, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
- and 20 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 24, 2026 · NCT07028853A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 24, 2026 · NCT07719361A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Sarah Cannon Research Institute Oncology Partners, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 22, 2026 · NCT07213674Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Tennessee Oncology PLLC, Chattanooga
RecruitingPhase 3
Ages 18 to 100 · Men · Updated Sep 22, 2026 · NCT06855277A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Nashville
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 18, 2026 · NCT06952803A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
- GSK Investigational Site, Nashville
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Sep 18, 2026 · NCT06990880High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- Memphis VA Medical Center, Memphis, TN, Memphis
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT05011383Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT07813637A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Memphis VA Medical Center ( Site 0072), Memphis
- SCRI Oncology Partners ( Site 0074), Nashville
- Henry-Joyce Cancer Clinic ( Site 0042), Nashville
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT06925737Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
- Sarah Cannon Research Institute Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT07493512Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Urology Associates of Nashville, Nashville
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT06056830A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06440005A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Sep 4, 2026 · NCT07567846Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
- SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 3, 2026 · NCT07545811A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Tennessee Oncology Nashville, Nashville
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 3, 2026 · NCT07005154AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, Nashville
RecruitingPhase 3
Ages 18 and older · Men · Updated Aug 26, 2026 · NCT07611110Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 2
Ages 18 and older · Men · Updated Aug 24, 2026 · NCT07745361Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- United States Oncology Regulatory Affairs Corporate Office, Nashville
RecruitingPhase 1
Ages 18 and older · Men · Updated Aug 21, 2026 · NCT04221542A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Henry-Joyce Cancer Clinic, Nashville
RecruitingPhase 2
Ages 18 and older · Men · Updated Aug 17, 2026 · NCT06842498FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Sarah Cannon Research, Nashville
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Aug 13, 2026 · NCT05519449Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Tennessee Oncology PLLC, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07288359Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #102, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT06545942PSMA PET Combined With MRI for the Detection of PCa
- The Conrad Pearson Clinic, Germantown
- Urology Associates of Nashville, Nashville
RecruitingPhase 3Healthy volunteers welcome
Ages 18 and older · Men · Updated Jul 23, 2026 · NCT07052214Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Vanderbilt University/Ingram Cancer Center, Nashville
RecruitingPhase 3
Ages 18 and older · Men · Updated Jul 14, 2026 · NCT06592924Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1
Ages 18 and older · Men · Updated Jul 2, 2026 · NCT07140900International Registry for Men With Advanced Prostate Cancer (IRONMAN)
- Memphis VA Medical Center, Memphis
- Baptist Clinical Research Institute, Memphis
RecruitingObservational study
Ages 21 and older · Men · Updated May 22, 2026 · NCT03151629Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06239194A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- Urology Associates PC, Nashville
RecruitingPhase 1
Ages 18 and older · Men · Updated Feb 4, 2026 · NCT04729114Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- The West Clinic - Wolf River, Germantown
RecruitingPhase 3
Ages 18 and older · Men · Updated Jan 22, 2026 · NCT06470243From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.